Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Listed as NCT03201146, this PHASE1/PHASE2 trial focuses on Apatinib and Combination Chemotherapy and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 6 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2020 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
- West China Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Chengdu, China